Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor

Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041.